247 related articles for article (PubMed ID: 9552061)
21. A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.
Abildgaard L; Ommen HB; Lausen B; Hasle H; Nyvold CG
Eur J Haematol; 2013 Nov; 91(5):394-8. PubMed ID: 23772754
[TBL] [Abstract][Full Text] [Related]
22. Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia.
Zhang L; Cao Z; Ruan M; Zeng Q; Zhao L; Li Q; Zou Y; Wang J; Zhu X
Pediatr Blood Cancer; 2014 Oct; 61(10):1761-6. PubMed ID: 24920269
[TBL] [Abstract][Full Text] [Related]
23. Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion.
van der Reijden BA; Simons A; Luiten E; van der Poel SC; Hogenbirk PE; Tönnissen E; Valk PJ; Löwenberg B; De Greef GE; Breuning MH; Jansen JH
Br J Haematol; 2002 Aug; 118(2):411-8. PubMed ID: 12139724
[TBL] [Abstract][Full Text] [Related]
24. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
[TBL] [Abstract][Full Text] [Related]
25. Fluorescence in situ hybridization identifies cryptic t(16;16)(p13;q22) masked by del(16)(q22) in a case of AML-M4 Eo.
Merchant SH; Haines S; Hall B; Hozier J; Viswanatha DS
J Mol Diagn; 2004 Aug; 6(3):271-4. PubMed ID: 15269306
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients.
Morschhauser F; Cayuela JM; Martini S; Baruchel A; Rousselot P; Socié G; Berthou P; Jouet JP; Straetmans N; Sigaux F; Fenaux P; Preudhomme C
J Clin Oncol; 2000 Feb; 18(4):788-94. PubMed ID: 10673520
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.
Corbacioglu A; Scholl C; Schlenk RF; Eiwen K; Du J; Bullinger L; Fröhling S; Reimer P; Rummel M; Derigs HG; Nachbaur D; Krauter J; Ganser A; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(23):3724-9. PubMed ID: 20625124
[TBL] [Abstract][Full Text] [Related]
28. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
Willekens C; Blanchet O; Renneville A; Cornillet-Lefebvre P; Pautas C; Guieze R; Ifrah N; Dombret H; Jourdan E; Preudhomme C; Boissel N;
Haematologica; 2016 Mar; 101(3):328-35. PubMed ID: 26635039
[TBL] [Abstract][Full Text] [Related]
29. Long-term disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBFbeta/MYH11 transcript.
Martinelli G; Ottaviani E; Testoni N; Montefusco V; Pastano R; Tura S
Haematologica; 2000 May; 85(5):552-5. PubMed ID: 10800179
[No Abstract] [Full Text] [Related]
30. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K;
Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435
[TBL] [Abstract][Full Text] [Related]
31. Rapid achievement of PML-RAR alpha polymerase chain reaction (PCR)-negativity by combined treatment with all-trans-retinoic acid and chemotherapy in acute promyelocytic leukemia: a pilot study.
Laczika K; Mitterbauer G; Korninger L; Knöbl P; Schwarzinger I; Kapiotis S; Haas OA; Kyrle PA; Pont J; Oehler L
Leukemia; 1994 Jan; 8(1):1-5. PubMed ID: 8289472
[TBL] [Abstract][Full Text] [Related]
32. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
[TBL] [Abstract][Full Text] [Related]
33. Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation.
Santini V; Zoccolante A; Bosi A; Guidi S; Saccardi R; Vannucchi AM; Martinazzo G; Bernabei PA; Ferrini PR
Haematologica; 1996; 81(3):201-7. PubMed ID: 8767524
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.
Ouyang J; Goswami M; Peng J; Zuo Z; Daver N; Borthakur G; Tang G; Medeiros LJ; Jorgensen JL; Ravandi F; Wang SA
Am J Clin Pathol; 2016 Jun; 145(6):769-77. PubMed ID: 27298396
[TBL] [Abstract][Full Text] [Related]
35. RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFβ-MYH11(+) acute myeloid leukemia.
Liu L; Yang L; Mi Y; Wang J; Li J; Zhang Y; Ma X; Qin T; Xu Z; Xiao Z
Leuk Res; 2011 Aug; 35(8):1020-6. PubMed ID: 21296419
[TBL] [Abstract][Full Text] [Related]
36. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
[TBL] [Abstract][Full Text] [Related]
37. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.
Viehmann S; Teigler-Schlegel A; Bruch J; Langebrake C; Reinhardt D; Harbott J
Leukemia; 2003 Jun; 17(6):1130-6. PubMed ID: 12764380
[TBL] [Abstract][Full Text] [Related]
38. Detection of minimal residual disease in a patient having acute myelogenous leukemia with t(16;21)(p11;q22) treated by allogeneic bone marrow transplantation.
Okoshi Y; Shimizu S; Kojima H; Obara N; Mukai HY; Komeno T; Hasegawa Y; Mori N; Nagasawa T
Acta Haematol; 2001; 105(1):45-8. PubMed ID: 11340253
[TBL] [Abstract][Full Text] [Related]
39. [Clinical and laboratory features of pediatric acute myeloid leukemia with inversion of chromosome 16].
He YX; Xue YQ; Wang HY; Yang NC; Shao XJ; Xu J; Ji ZH; Huang YP; Ding YF; Hu SY
Zhonghua Er Ke Za Zhi; 2012 Aug; 50(8):593-7. PubMed ID: 23158736
[TBL] [Abstract][Full Text] [Related]
40. A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse.
Lane S; Saal R; Mollee P; Jones M; Grigg A; Taylor K; Seymour J; Kennedy G; Williams B; Grimmett K; Griffiths V; Gill D; Hourigan M; Marlton P
Leuk Lymphoma; 2008 Mar; 49(3):517-23. PubMed ID: 18297529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
